Korea Research Institute of Bioscience and Biotechnology

Enzychem Lifesciences Corporation

Yungjin Pharmaceutical Co., Ltd.

Sungkyunkwan University

Dongguk University Industry-Academic Cooperation Foundation

Korea Institute of Bioscience and Biotechnology

Sei-Ryang Oh

Kyung Seop Ahn

Ok-Kyoung Kwon

Doo-Young Kim

Yong-Hae Han

Jung-hee Kim

Dae-Hee Shin

Ji-Seok Yoo

Byung-Hwan Ryoo

Ki Young Sohn

Ji-seok Yoo

Dae-hee Shin

Byung-hwan Ryoo

Su Ui Lee

Yongnam Lee

Tae-Suk Lee

Kyung-seop Ahn

JongKoo Kang

Hyeongkyu Lee

Hyuk-hwan Song

Hyuk-Hwan Song

Kyung-Seop Ahn

Jae Wha Kim

Jung Hee Kim

Hyung Won Ryu

In Sik Shin

Jung-Hee Kim

Ho Bum Kang

Young-Sik Jung

Hye Kyung Kim

Hyeong-Kyu Lee

Na-Rae Shin

Jongkoo Kang

Soo Hyun Kim

Kyeong Seok Lee

Sang Ho Choi

Sang-Woo Lee

Hyeong Kyu Lee

Doo Young Kim

Ki-Young Sohn

Jung Weon Lee

Sangku Lee

Seung Hyung Kim

Myung Hwan Kim

Joongku Lee

Wan Yi Li

Tae Suk Lee

Jong Koo Kang

Hyuk Hwan Song

Jae Sung Song

Jae Min Shin

Hang Jin

InPyo Choi

Hyun-Jun Lee

Young Eun Ko

Choon Gon Jang

Jin Soo Yook

Seung Hwan Kwon

Ho-Bum Kang

Kyungseop Ahn

In-Sik Shin

Ho-Jae Lee

Eun-Ah Kim

Soon-Ja Choi

Su-Yong Choi

Xuezhen Xu

Chan Mi Chun

Jae Mine Yoo

Suui Lee

The present invention relates to a pharmaceutical composition containing a monoacetyldiacyiglycerol compound as an active ingredient for preventing or treating asthma, and a functional health food composition for preventing or treating asthma. The monoacetyldiacylglycerol compound of the present invention inhibits the expression of IL-4 in EL-4 cells, which are mouse T cell lymphoma cells, reduces hypersensitivity of airway in an asthma-induced animal model, and inhibits the infiltration of inflammatory cells into the bronchial tube. In addition, the compounds of the present invention inhibit the generation of IgE in the serum and bronchoalveolar lavage fluid, have an excellent effect of inhibiting the expression of Th2 cytokines (IL-4, IL-5, and IL-13) in the lung, thereby overcome side effects of the currently used therapeutic agents for asthma, have no toxicity, and exhibit a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating asthma.

Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating asthma

The present invention relates to a composition containing a monoacetyldiglyceride compound as an active ingredient, for inhibiting blood cancer or metastasis, and a use thereof. The monoacetyldiglyceride compound according to the present invention has excellent effects of inhibiting the expression of IL-4 and inhibiting the activity of STAT-6, and thereby is capable of overcoming side effects of currently used blood cancer or metastasis inhibiting agents. Also, the monoacetyldiglyceride compound is a non-toxic compound having superior therapeutic effects and thus can be useful as a composition for preventing, treating, or improving blood cancer and metastasis.

Composition containing monoacetyldiacylglycerol compound as active ingredient for inhibiting blood cancer or metastasis

The present invention relates to a pharmaceutical composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing or treating chronic obstructive pulmonary diseases, and a functional health food composition for treating or preventing chronic obstructive pulmonary diseases. The monoacetyldiacylglycerol compound of the present invention inhibits the IL-4 expression in EL-4 cells and inhibits the infiltration of inflammatory cells into the bronchial tube in an animal model. In addition, the compounds of the present invention have an excellent effect of inhibiting the expression of CXCL-1, TNF-&#x3b1;, or MIP-2, thereby overcoming side effects of the currently used therapeutic agents for chronic obstructive pulmonary diseases, having no toxicity, and exhibiting a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating chronic obstructive pulmonary diseases.

Composition containing monoacetyldiglyceride compound as active ingredient for preventing or treating chronic obstructive pulmonary disease

The present invention relates to a pharmaceutical composition and a food composition containingHook. extract or a fraction thereof as an active ingredient for preventing, treating or ameliorating neuroinflammation or neuro-degenerative diseases. TheHook. extract or a fraction thereof according to the present invention is derived from a natural product which has been in use as a natural medicinal ingredient, and as such, has no side effects and inhibits expression of NO, PGE, iNOS and/or COX-2 genes or protein, which are factors associated with inflammation, and is additionally superbly effective for increasing and improving memory and the ability to learn, and thus can be beneficially used to prevent or treat neuroinflammation or neuro-degenerative diseases.

Method for treating neuroinflammation with a pharmaceutical composition containinghook. extract or fraction thereof as active ingredient

A pharmaceutical composition includes any of an extract of, a fraction or an active fraction obtained by fractionation thereof with an organic solvent, and a compound separated therefrom as an active ingredient. The extract of, the fraction or the active fraction obtained by fractionation thereof with an organic solvent, or the compound separated therefrom inhibits the expression of MUC5AC induced by TNF-&#x3b1; and the promoter activity in human lung cancer mucosal cells (H292), reduces the number of inflammatory cells in the bronchoalveolar lavage fluid of the chronic obstructive pulmonary disease mouse model, inhibits the production of reactive oxygen species, and reduces the cytokines; and therefore are effective in preventing or treating chronic obstructive pulmonary disease.

Pharmaceutical composition for preventing and treating chronic obstructive lung disease containing, as active ingredient,extract, fraction, or active fraction thereof

The present invention relates to a pharmaceutical composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing or treating asthma, and a functional health food composition for preventing or treating asthma. The monoacetyldiacylglycerol compound of the present invention inhibits the expression of IL-4 in EL-4 cells, which are mouse T cell lymphoma cells, reduces hypersensitivity of airway in an asthma-induced animal model, and inhibits the infiltration of inflammatory cells into the bronchial tube. In addition, the compounds of the present invention inhibit the generation of IgE in the serum and bronchoalveolar lavage fluid, have an excellent effect of inhibiting the expression of Th2 cytokines (IL-4, IL-5, and IL-13) in the lung, thereby overcome side effects of the currently used therapeutic agents for asthma, have no toxicity, and exhibit a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating asthma.

The present invention relates to a novel 2-phenylbenzofuran derivative or a pharmaceutically acceptable salt thereof, a production method for the same, and a pharmaceutical composition for preventing or treating an inflammatory disease comprising the same as an active ingredient, and the novel 2-phenylbenzofuran derivative or the pharmaceutically acceptable salt thereof according to the present invention is outstandingly effective in suppressing NO, IL-6, and TNF-alpha induced by macrophages, and therefore can advantageously be used in a pharmaceutical composition for preventing or treating an inflammatory disease.

2-phenylbenzofuran derivatives, method for preparing the same and use of the same for treating inflammatory disease

The present invention relates to inventive novel industrialized method for preparing purified extract containing more abundant active ingredients such as catalpol derivatives from the extract ofvarthan that prepared by the conventional preparation method disclosed in the prior art and the therapeutics or functional health food comprising the purified extract for treating and preventing inflammatory, allergic or asthmatic disease. The purified extract showed more potent anti-inflammatory, anti-allergy and anti-asthma activity than that prepared by the conventional preparation method disclosed in the prior art through various in vivo tests such as inhibition test on the reproduction of eosinophil, the release of immunoglobulin and inflammatory chemokines in plasma and bronchoalveolar fluid as well as the suppression of airway hyperresponsiveness and goblet cell hyperplasia in a OVA-sensitized/challenged mouse model.

[object Object]

The present invention relates to a pharmaceutical composition, functional health food composition, quasi-drug composition, and cosmetic composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing, treating or improving atopic dermatitis. The monoacetyldiacylglycerol compound of the present invention has an excellent effect of suppression of IL-4 and IgE secretion, thereby overcoming side effects of an atopic dermatitis treatment agent currently in use, having no toxicity, and exhibiting an excellent treatment effect, and thus can be useful as a composition for preventing, treating, and ameliorating atopic dermatitis.

Composition containing monoacetyldiglyceride compound as active ingredient for preventing or treating atopic dermatitis

A method for preparing purified extract containing more abundant active ingredients such as catalpol derivatives from the extract ofvarthan that prepared by the conventional preparation method disclosed in the prior art and the therapeutics or functional health food comprising the purified extract for treating and preventing inflammatory, allergic or asthmatic disease. The purified extract showed more potent anti-inflammatory, anti-allergy and anti-asthma activity than that prepared by the conventional preparation method disclosed in the prior art through various in vivo tests such as inhibition test on the reproduction of eosinophil, the release of immunoglobulin and inflammatory chemokines in plasma and bronchoalveolar fluid as well as the suppression of airway hyperresponsiveness and goblet cell hyperplasia in a OVA-sensitized/challenged mouse model.

The present invention relates to an antiviral composition containing anorextract or a fraction thereof as an active ingredient. In detail, extracts oforor fractions thereof can induce the secretion of an immune-related cytokine, interferon-&#x3b3; (IFN-&#x3b3;) in natural killer (NK) cells, and thus exhibit potent antiviral activity and superior effects for viral diseases, and therefore can be effectively used in an antiviral composition.

The present invention relates to an anoikis-inducing agent comprising aextract, a tiarellic acid compound isolated therefrom or a pharmaceutically acceptable salt thereof, which is specific to cancer cells expressing a tumor-associated antigen L6 or a homolog thereof. Theextract, the tiarellic acid compound isolated therefrom or pharmaceutically acceptable salt thereof of the present invention leads to loss of cell adhesion to reduce cancer cell proliferation and exhibits the effect of inducing cell death in cancer cells expressing a tumor-associated antigen L6 or a homolog thereof, thereby being used for preventing and treating cancer diseases due to a tumor-associated antigen L6 or a homolog thereof.

Growing community of inventors

Daejeon, South Korea

Sei-Ryang Oh